OKYO Pharma Ltd.
OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases. The company concentrates on ophthalmology and corneal health, with research programs aimed at conditions such as dry eye disease, allergic conjunctivitis, uveitis, and ocular pain. Its pipeline includes urcosimod, an investigational candidate being studied for multiple eye-related indications, and OK-201, another development-stage therapy for ocular pain. OKYO Pharma Ltd. operates as a research and development business in the healthcare sector, targeting unmet needs in diseases affecting the cornea and anterior segment of the eye. Based in London and incorporated in Guernsey, the company plays a specialized role in the biopharmaceutical market by advancing non-opioid and non-steroidal treatment approaches for complex eye disorders.
$1.54
+$0.02 (+1.32%)
Price from 31 days ago
Negative free cash flow of -$6M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$9M
▼ -90.2% YoY
Op. Margin
—
ROIC
-108.87%
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▼ -227.9% YoY
Op. Cash Flow (TTM)
-$6M
▼ -227.8% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$21M
Continue Research
Is OKYO Pharma (OKYO) overvalued?
OKYO Pharma (OKYO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, OKYO Pharma scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology. This is analysis, not investment advice.
Frequently asked
Is OKYO Pharma a high-quality business?+
OKYO Pharma scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -108.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is OKYO Pharma a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh OKYO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.